Antioxidants: The good, the bad and the ugly

Canadian Journal of Cardiology

Volumn 22, Issue SUPPL. B, 2006, Pages 61B-65B

  Tardif, Jean Claude ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

Antioxidants; Atherosclerosis; Inflammmation; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FREE RADICAL; LOW DENSITY LIPOPROTEIN; OMEGA 3 FATTY ACID; PLACEBO; PROBUCOL; PROBUCOL SUCCINATE; RETINOL; SIMVASTATIN; VASCULAR CELL ADHESION MOLECULE 1; VITAMIN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL DIAMETER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG SOLUBILITY; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; IN-STENT RESTENOSIS; INTRAVASCULAR ULTRASOUND; LIPID PEROXIDATION; MORBIDITY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; RESTENOSIS;

EID: 33845339016     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0828-282x(06)70988-6     Document Type: Article

References (53)

1. Ross R. Atherosclerosis - An inflammatory disease. N Engl J Med 1999;340:115-26.
2. Kunsch C, Medford RM. Oxidative stress as a regulator of gene expression in the vasculature. Circ Res 1999;85:753-66.
3. Cushing SD, Berliner JA, Valente AJ, et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 1990;87:5134-8.
4. Marui N, Offermann MK, Swerlick R, et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993;92:1866-74.
5. Rajavashisth TB, Andalibi A, Territo MC, et al. Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature 1990;344:254-7.
6. Bourcier T, Sukhova G, Libby P. The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis. J Biol Chem 1997;272:15817-24.
7. Thomas CE, Jackson RL, Ohlweiler DF, Ku G. Multiple lipid oxidation products in low density lipoproteins induce interleukin-1 beta release from human blood mononuclear cells. J Lipid Res 1994;35:417-27.
8. Rajagopalan S, Meng XF, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996;98:2572-9.
9. Ikeda H, Koga Y, Oda T, et al. Free oxygen radicals contribute to platelet aggregation and cyclic flow variations in stenosed and endothelium-injured canine coronary arteries. J Am Coll Cardiol 1994;24:1749-56.
10. Roberts MJ, Young IS, Trouton TG, et al. Transient release of lipid peroxides after coronary artery balloon angioplasty. Lancet 1990;336:143-5.
11. Iuliano L, Pratico D, Greco C, et al. Angioplasty increases coronary sinus F2-isoprostane formation: Evidence for in vivo oxidative stress during PTCA. J Am Coll Cardiol 2001;37:76-80.
12. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990;344:160-2.
13. Tardif J-C, Gregoire J, Bourassa MG. Antioxidants and restenosis - human studies. Tardif J-C, Bourassa MG, eds. In: Antioxidants and Cardiovascular Disease. Netherlands: Kluwer Academic Press, 2000:175-94.
14. Christen WG, Hennekens CH. Antioxidant vitamins and cardiovascular disease: Evidence from observational epidemiologic studies and randomized trials. Tardif J-C, Bourassa MG, eds. In: Antioxidants and Cardiovascular Disease. Netherlands: Kluwer Academic Press, 2000:135-44.
15. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-35.
16. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150-5.
17. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781-6.
18. Gruppo Italiano per lo Studio della Sopravivenza nell'Infarcto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Lancet 1999;354:447-55. (Erratum in 2001;357:642).
19. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:154-60.
20. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: Early safety and efficacy experience. Eur Heart J 1999;20:725-41.
21. Bowry VW, Ingold KU, Stocker R. Vitamin E in human low-density lipoprotein. When and how this antioxidant becomes a pro-oxidant. Biochem J 1992;288:341-4.
22. Keaney JF Jr, Gaziano JM, Xu A, et at. Low-dose alpha-tocopherol improves and high-dose alpha-tocopherol worsens endothelial vasodilator function in cholesterol-fed rabbits. J Clin Invest 1994;93:844-51.
23. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: A randomized controlled trial. JAMA 2002;288:2432-40.
24. Tardif J-C, Cote G, Lesperance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med 1997;337:365-72.
25. Brown BG, Zhao X-Q, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92.
26. Rodes J, Cote G, Lesperance J, et al. Prevention of restenosis after angioplasty in small coronary arteries with probucol. Circulation 1998;97:429-36.
27. Cote G, Tardif J-C, Lesperance J, et al. Effects of probucol on vascular remodeling after coronary angioplasty. Circulation 1999;99:30-5.
28. Fems GA, Forster L, Stewaff~Lee A, Konneh M, Nourooz-Zadeh J, Anggard EE. Probucol inhibits neointirnal thickening and macrophage accumulation after balloon injury in the cholesterol-fed rabbit. Proc Natl Acad Sci USA 1992;89:11312-6.
29. Schneider JE, Berk BC, Gravanis MB, et al. Probucol decreases neointimal formation in a swine model of coronary artery balloon injury. A possible role for antioxidants in restenosis. Circulation 1993;88:628-37.
30. Freyschuss A, Stiko-Rahm A, Swedenborg J, et al. Antioxidant treatment inhibits the development of intimal thickening after balloon injury of the aorta in hypercholesterolemic rabbits. J Clin Invest 1993;91:1282-8.
31. Nunes GL, Sgoutas DS, Redden RA, et al. Combination of vitamins C and E alters the response to coronary balloon injury in the pig. Arterioscler Thromb Vase Biol 1995;15:156-65.
32. Lafont A, Vinchon F, Addad F, et al. Antioxidants and restenosis: Animal studies. In: Tardif J-C, Bourassa MG, eds. Antioxidants and Cardiovascular Disease. Netherlands: Kluwer Academic Press, 2000:161-74.
33. Lau AK, Leichtweis SB, Hume P, et al. Probucol promotes functional reendothelialization. in balloon-injured rabbit aortas. Circulation 2003;107:2031-6.
34. Setsuda M, Inden M, Hiraoka N, et al. Probucol therapy in the prevention of restenosis after successful percutaneous transluminal coronary angioplasty. Clin Ther 1993;15:374-82.
35. Watanabe K, Sekyia M, Ikeda S, Miyagawa M, Hashida. K. Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1996;132:23-9.
36. Lee YJ, Daida H, Yokoi H, et al. Effectiveness of probucol in preventing restenosis after percutaneous transluminal coronary angioplasty. Jpn Heart J 1996;37:327-32.
37. Tardif J-C, Cote G, Lesperance J, et al. Impact of residual plaque burden after balloon angioplasty in the MultiVitamins and Probucol (MVP) trial. Can J Cardiol 2001;17:49-55.
38. Yokoi H, Daida. H, Kuwabara Y, et al. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: The Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol 1997;30:855-62.
39. Tardif J-C, Gregoire J, Schwartz L, et al. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation 2003;107:552-8.
40. Meng CQ, Somers PK, Rachita. CL, et al. Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis. Bioorg Med Chem Lett 2002;12:2545-8.
41. Wasserman MA, Sundell CL, Kunsch C, Edwards D, Meng CQ, Medford RM. Chemistry and pharmacology of vascular protectants: A novel approach to the treatment of atherosclerosis and coronary artery disease. Am J Cardiol 2003;91(Suppl):34A-40A.
42. Kunsch C, Luchoomun J, Grey JY, et al. Selective inhibition of endothelial and monocyte redox-sensitive genes by AGI-1067: A novel antioxidant and anti-inflammatory agent. J Pharmacol Exp Ther 2004;308:820-9.
43. Sundell CL, Somers PK, Meng CQ, et al. AGI-1067: A multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent. J Pharmacol Exp Ther 2003;305:1116-23.
44. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995;332:488-93.
45. McLean LR, Thomas CE, Weintraub B, Hagaman. Modulation of the physical state of cellular cholesteryl esters by 4,4′-(isopropylidenedithio)bis(2,6-di-t-butylphenol) (probucol). J Biol Chem 1992;267:12291-8.
46. Tardif J-C. Clinical results with AGI-1067: A novel antioxidant vascular protectant. Am J Cardiol 2003;91(Suppl):41A-49A.
47. Sawayama Y, Shimizu C, Maeda N, et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 2002;39:610-6.
48. Walldius G, Erikson U, Olsson AG, et al. The effect of probucol on femoral atherosclerosis: The Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994;74:875-83.
49. Sasahara M, Raines EW, Chait A, et al. Inhibition of hypercholesterolemia-induced atherosclerosis in the non-human primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation? J Clin Invest 1994;94:155-64.
50. Guedes A, Tardif J.C. Intravascular ultrasound assessment of atherosclerosis. Curr Atheroscler Rep 2004;6:219-24.
51. 2- production in the pig coronary artery. Circulation 1997;96:3593-601.
52. Tardif J-C, Gregoire J, L'Allier PL. Prevention of restenosis with antioxidants: Mechanisms and implications. Am J Cardiovasc Drugs 2002;2:323-34.
53. Tardif J-C. Insights into oxidative stress and atherosclerosis. Can J Cardiol 2000;16(Suppl D):2D-4D.